- Conditions
- Disease, Hodgkin
- Interventions
- brentuximab vedotin, placebo
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 32
- States / cities
- Duarte, California • San Francisco, California • Stanford, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 2,695
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Arteriosclerosis, Coronary Artery Bypass Graft, Myocardial Revascularization
- Interventions
- Autologous stem cell therapy, CABG, CMRI
- Procedure · Radiation
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Stage III Melanoma, Stage IV Melanoma
- Interventions
- TBX-3400
- Biological
- Lead sponsor
- Taiga Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Denver, Colorado
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Interventions
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide, Etoposide, Fludarabine Phosphate
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Knee Pain Chronic, Osteo Arthritis Knee
- Interventions
- HB-adMSC
- Biological
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Orleans, Louisiana • Kansas City, Missouri + 1 more
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of Liver
- Interventions
- 21.15.GPC3-CAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2043
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- INTERCEPT Treated Platelets
- Device
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Seattle, Washington
- Conditions
- Healthy
- Interventions
- EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
- Drug
- Lead sponsor
- Quince Therapeutics S.p.A.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin
- Interventions
- Carmustine, Etoposide phosphate, Cytarabine, Melphalan HCl (propylene glycol-free)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lymphoma, T-Cell
- Interventions
- Genetic: MB-105
- Biological
- Lead sponsor
- March Biosciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- San Diego, California • Denver, Colorado • Tampa, Florida + 8 more
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Patients With Residual or Reccurent EGFRvIII+ Glioma
- Interventions
- CART-EGFRvIII T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
- Interventions
- Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
- Interventions
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida
- Conditions
- Amputation, Skin Wound, Stem Cell
- Interventions
- Autologous Skin Fibroblasts, Placebo
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, modified T cells
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms
- Interventions
- GSK3845097, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
- Conditions
- Advanced Prostate Cancer, Prostatic Neoplasms
- Interventions
- sipuleucel-T
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 333
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 245 more
- Conditions
- AML
- Interventions
- AMLCTL
- Biological
- Lead sponsor
- Thomas A. Lane, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Relapsed/Refractory Aggressive B-Cell Malignancies
- Interventions
- ONCT-808, Bridging Therapy
- Biological · Drug
- Lead sponsor
- Oncternal Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- DC vaccine, Bevacizumab, IL-2, IFN
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Hypoplastic Left Heart Syndrome (HLHS)
- Interventions
- Collection of umbilical cord blood
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Female only
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Pain, Osteoarthritis
- Interventions
- APIC-CF, 4 cc, APIC-CF, 2 cc, Placebo Comparator: Saline
- Device · Other
- Lead sponsor
- Cytonics Corporation
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Townsend, Maryland